Untangling the Benefits of Drug-Eluting Stents in STEMI Patients

Long-term findings from HORIZONS-AMI confirm a reduction in restenosis but also reveal the effects of planned angiographic follow-up.

In the HORIZONS-AMI trial (JW Cardiol May 6 2009), involving 3006 patients undergoing primary percutaneous coronary intervention (PCI) for ST-segment-elevation myocardial infarction (STEMI), the rate of ischemic target-lesion revascularization (TLR) at 12 months was 4.5% in drug-eluting stent (DES) recipients versus 7.5% in bare-metal stent (BMS) recipients (P=0.003). Now, the HORIZONS-AMI investigators have retrospectively assessed 2-year revascularization rates as well as the effects of a planned 13-month angiographic follow-up in half of the patients enrolled.

Angiography was performed in 1203 patients, 1010 of whom had no clinical indication for the procedure. Angiographic restenosis was found in 23% of BMS recipients and 10% of DES reci…

Reviewing Author

Howard C. Herrmann, MD

Disclosures

Consultant/Advisory BoardAffluent Medical; Artedrone; Caranx; Johnson & Johnson; Medtronic; Prolifagen; Wells Fargo

EquityMicrointerventional Devices, Inc.

RoyaltiesUniversity of Pennsylvania

Grant/Research SupportAbbott Vascular; Edwards Lifesciences; Johnson & Johnson; Medtronic

Editorial BoardsCatheterization and Cardiovascular Interventions; Journal of the American College of Cardiology; Circulation: Cardiovascular Interventions; JACC Cardiovascular Interventions; JACC Case Reports; JSCAI